Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00324220 · ClinicalTrials.gov registry record · Phase 1
A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia
A Phase 1 study of Myelodysplastic Syndrome and Acute Myelogenous Leukemia, sponsored by Mirati Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
- 8
- Study locations
NCT00324220 is a Phase 1 study of Myelodysplastic Syndrome and Acute Myelogenous Leukemia that has completed, run by Mirati Therapeutics. The registered enrollment target is 66 participants, below the 207-participant average among 134 other Myelodysplastic Syndrome trials with a reported enrollment target (68% lower). The trial reports 8 study locations across 5 states.
The verdict
NCT00324220, a Phase 1 study of Myelodysplastic Syndrome and Acute Myelogenous Leukemia, has completed, sponsored by Mirati Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
- 8
- Study locations
Study Summary
In this study, MGCD0103, a new anticancer drug under investigation, is given three times weekly in combination with azacitidine to patients with high-risk myelodysplastic syndromes or acute myelogenous leukemia.
Conditions Studied
Interventions
- DRUG MGCD0103
Study Locations (8)
Pennsylvania
- University of Pennsylvania - Philadelphia
- Thomas Jefferson University Hospital - Philadelphia
- Thomas Jefferson University - Philadelphia
- The Western Pennsylvania Hospital - Pittsburgh
California
- University of Southern California - Los Angeles
Indiana
- St. Francis Hospital & Health Center - Beech Grove
New York
- Memorial Sloan-Kettering Cancer Center - New York
Texas
- University of Texas, MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2006-01 |
| Est. Completion | 2008-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00324220
The ClinicalTrials.gov registry entry for NCT00324220 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 207-participant average among 134 other Myelodysplastic Syndrome trials with a reported enrollment target (68% lower). The listed sponsor is Mirati Therapeutics, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Myelodysplastic Syndrome appearing as the primary indexed condition, and to 1 intervention - of which MGCD0103 is the first listed.
NCT00324220 reports 8 study locations spanning 5 distinct geographic areas - top geographies include Pennsylvania, California, Indiana.
Frequently Asked Questions
What is clinical trial NCT00324220 about?
NCT00324220 is a clinical study titled "A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia". In this study, MGCD0103, a new anticancer drug under investigation, is given three times weekly in combination with azacitidine to patients with high-risk myelodysplastic syndromes or acute myelogenous leukemia.
What is the current status of trial NCT00324220?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2006-01. Estimated completion is 2008-11.
What conditions does trial NCT00324220 study?
This clinical trial studies the following conditions: Myelodysplastic Syndrome, Acute Myelogenous Leukemia.
What interventions are being tested in trial NCT00324220?
The interventions under investigation include: MGCD0103 (DRUG).
Who is sponsoring clinical trial NCT00324220?
This trial is sponsored by Mirati Therapeutics, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00324220 being conducted?
This trial has 8 study locations across California, Indiana, New York, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelodysplastic Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
RECRUITING · Phase 1
-
FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RECRUITING · Phase 1
-
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RECRUITING · Phase 1
-
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
RECRUITING · Phase 1
-
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.